Edition:
United States

Lexicon Pharmaceuticals Inc (LXRX.O)

LXRX.O on Nasdaq

14.69USD
29 Mar 2017
Change (% chg)

$0.53 (+3.74%)
Prev Close
$14.16
Open
$14.17
Day's High
$14.85
Day's Low
$14.10
Volume
1,201,449
Avg. Vol
809,647
52-wk High
$19.62
52-wk Low
$11.28

Latest Key Developments (Source: Significant Developments)

Lexicon Pharma files for offering of up to $10.1 mln by selling stockholders - SEC filing
Monday, 20 Mar 2017 10:34am EDT 

Lexicon Pharmaceuticals Inc :Files for secondary offering of up to $10.1 million by selling stockholders - SEC filing.  Full Article

Lexicon Pharmaceuticals reports Q4 loss per share $0.31
Friday, 3 Mar 2017 07:00am EST 

Lexicon Pharmaceuticals Inc : Lexicon Pharmaceuticals provides clinical pipeline update and reports 2016 fourth quarter and full year financial results . Q4 revenue $23 million versus $127.3 million . Q4 revenue view $15.6 million -- Thomson Reuters I/B/E/S . Q4 loss per share $0.31 .Q4 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

Lexicon reports top-line results from phase 2 clinical trial conducted in collaboration with JDRF
Monday, 5 Dec 2016 04:01pm EST 

Lexicon Pharmaceuticals Inc : Lexicon reports top-line results from phase 2 clinical trial conducted in collaboration with JDRF . Lexicon Pharmaceuticals-sotagliflozin was well tolerated in study, smaller proportion of patients experiencing treatment-emergent adverse events . Results for a1c primary endpoint numerically favored sotagliflozin, but did not reach statistical significance .Lexicon Pharmaceuticals-patients treated with sotagliflozin achieved mean reduction of 0.62 kg in body weight from baseline to week 12, compared to placebo.  Full Article

Lexicon Pharmaceuticals agrees to buy remaining obligations to Symphony Icon
Wednesday, 5 Oct 2016 07:00am EDT 

Lexicon Pharmaceuticals Inc: Lexicon Pharmaceuticals announces agreement to buy out remaining obligations to Symphony Icon . Buyout payment may be payable in cash or a combination of cash and up to 50% in lexicon common stock, at Lexicon's option . Lexicon will make a single payment to Symphony Icon of $21.013 million .Buyout to replace, eliminate remaining contingent payments of up to $29.550 million for which co was obligated.  Full Article

Lexicon Pharmaceuticals Q2 loss per share $0.37
Thursday, 4 Aug 2016 07:00am EDT 

Lexicon Pharmaceuticals Inc : Q2 loss per share $0.37 . Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S . Q2 revenue view $12.4 million -- Thomson Reuters I/B/E/S .Q2 revenue $20.1 million versus $400,000.  Full Article

Lexicon announces FDA priority review of new drug application
Tuesday, 31 May 2016 08:00am EDT 

Lexicon Pharmaceuticals Inc : FDA has granted a priority review of NDA filing and set a PDUFA target action date of November 30, 2016 .Lexicon announces fda priority review of new drug application for Telotristat Etiprate for the treatment of carcinoid syndrome.  Full Article

Ipsen's Partner, Lexicon Pharmaceuticals announces positive results from TELESTAR Phase 3 study showing that telotristat Etiprate is effective
Monday, 3 Aug 2015 01:00am EDT 

Lexicon Pharmaceuticals:Says positive results from TELESTAR Phase 3 study showing that telotristat etiprate is Effective in treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs.Telotristat etiprate met the primary endpoint, i.e. reduction from baseline compared to placebo in the average number of daily bowel movements over the 12-week study period.Ipsen owns global commercial rights to telotristat etiprate (excluding the US and Japan).  Full Article

More From Around the Web

BRIEF-Lexicon Pharma files for offering of up to $10.1 mln by selling stockholders - SEC filing

* Files for secondary offering of up to $10.1 million by selling stockholders - SEC filing Source text - http://bit.ly/2nD7v4q Further company coverage: